← Eichor
Study identifier: NCT07449741 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Phase I Study of HXN6005 in Adult Healthy Participants

Condition: Healthy Volunteers (HV)  ·  Sponsor: Helixon Biotechnology (Suzhou) Co., Ltd

PhasePhase 1
Planned participants32
Who can joinAll sexes, 18 Years to 55 Years
Healthy volunteersYes

About this study

The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetic characteristics and pharmacodynamics of HXN6005 in Healthy Participants. Researchers will compare HXN6005 to a placebo (a look-alike substance that contains no drug). Participants will take a single dose of HXN6005 or placebo on Day 1, and visit the clinic for followup and tests per the protocol scheme.

This description comes directly from the study's public registry record.

Talk to the study team

Gang Tong  ·  (86)13918569690  ·  tonggang@helixon.com

Always discuss trial participation with your own doctor first.

Locations (1)

Veritus ResearchBayswater, Victoria, AustraliaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07449741